Should I buy or sell Evogene stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVGN shares. View EVGN analyst ratings or view top-rated stocks .

What is Evogene's stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for Evogene's shares. Their EVGN share price targets range from $1.85 to $6.00. On average, they anticipate the company's stock price to reach $3.62 in the next twelve months. This suggests a possible upside of 491.0% from the stock's current price. View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts .

How have EVGN shares performed in 2024?

Evogene's stock was trading at $0.84 on January 1st, 2024. Since then, EVGN shares have decreased by 27.1% and is now trading at $0.6120. View the best growth stocks for 2024 here .

Are investors shorting Evogene?

Evogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 86,500 shares, an increase of 20.8% from the March 15th total of 71,600 shares. Based on an average trading volume of 173,900 shares, the days-to-cover ratio is currently 0.5 days. View Evogene's Short Interest .

When is Evogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our EVGN earnings forecast .

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $0.58 million for the quarter, compared to analysts' expectations of $1.73 million. Evogene had a negative net margin of 423.39% and a negative trailing twelve-month return on equity of 76.93%. During the same quarter last year, the firm posted ($0.07) earnings per share.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include AbbVie (ABBV) , AcelRx Pharmaceuticals (ACRX) , Allena Pharmaceuticals (ALNA) , Dynavax Technologies (DVAX) , Energy Transfer (ET) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Abbott Laboratories (ABT) , Acasti Pharma (ACST) and Akari Therapeutics (AKTX) .

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EVGN

Evogene (EVGN) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free EVGN Stock Alerts

$0.61

-0.03 (-4.67%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.61
▼
$0.66
50-Day Range: $0.64
▼
$0.98
52-Week Range: $0.45
▼
$1.44

Volume: 72,092 shs
Average Volume: 171,270 shs
Market Capitalization: $25.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.62

Get Evogene alerts:

Evogene MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 491.0% Upside
$3.62 Price Target
Short Interest: Healthy
0.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

771st out of 911 stocks

Agricultural Chemicals Industry

9th out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
Evogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Evogene has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.21% of the outstanding shares of Evogene have been sold short.
Short Interest Ratio / Days to Cover
Evogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Evogene has recently increased by 20.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Evogene does not currently pay a dividend.
Dividend Growth
Evogene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVGN.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Evogene this week, compared to 1 article on an average week.
MarketBeat Follows
4 people have added Evogene to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evogene insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Evogene is held by insiders.
Percentage Held by Institutions
Only 10.40% of the stock of Evogene is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Evogene is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evogene is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evogene has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Evogene Stock (NASDAQ:EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

EVGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVGN Stock News Headlines

April 16, 2024 | americanbankingnews.com

Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

April 11, 2024 | prnewswire.com

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | finance.yahoo.com

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

March 28, 2024 | prnewswire.com

Evogene Announces Filing of Annual Report on Form 20-F

March 20, 2024 | prnewswire.com

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

March 19, 2024 | prnewswire.com

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

March 8, 2024 | finance.yahoo.com

Evogene Ltd. (NASDAQ:EVGN) Q4 2023 Earnings Call Transcript

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 7, 2024 | investorplace.com

EVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023

March 7, 2024 | de.investing.com

Evogene: EPS übertrifft Schätzungen um 0,01 $ - Umsatz schlechter als erwartet

March 7, 2024 | finance.yahoo.com

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

March 6, 2024 | finanznachrichten.de

AgPlenus Ltd.: AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

March 6, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Evogene's earnings report

March 6, 2024 | benzinga.com

Evogene Earnings Preview

March 6, 2024 | finance.yahoo.com

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

March 5, 2024 | prnewswire.com

Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties

February 28, 2024 | prnewswire.com

Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements

February 26, 2024 | finance.yahoo.com

Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024

February 26, 2024 | prnewswire.com

Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024

February 22, 2024 | prnewswire.com

AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer

February 21, 2024 | finanznachrichten.de

Bayer schwankt, deutliche Gewinnmitnahmen bei Renk, Zweifel um Nvidia und auch bei Super Micro Computer ist die Luft raus

February 21, 2024 | finance.yahoo.com

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution

February 21, 2024 | prnewswire.com

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution

February 20, 2024 | businesswire.com

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide

February 20, 2024 | prnewswire.com

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide

January 17, 2024 | finanznachrichten.de

Biomica Ltd.: Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

See More Headlines

Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Agricultural chemicals
Sub-Industry: N/A
Current Symbol: NASDAQ:EVGN
CUSIP: N/A
CIK: 1574565
Web: www.evogene.com
Phone: (728) 931-1900
Fax: 972-8946-6724
Employees: 142
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.62
High Stock Price Target: $6.00
Low Stock Price Target: $1.85
Potential Upside/Downside: +464.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,880,000.00
Net Margins: -423.39%
Pretax Margin: -460.76%
Return on Equity: -76.93%
Return on Assets: -45.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.96
Quick Ratio: 4.95

Sales & Book Value

Annual Sales: $5.64 million
Price / Sales: 4.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 0.92

Miscellaneous

Outstanding Shares: 41,220,000
Free Float: 38,166,000
Market Cap: $26.41 million
Optionable: Optionable
Beta: 1.49

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Ofer Haviv CPA (Age 58)
CEO & President
Comp: $390k
Dr. Nir Arbel (Age 44)
Chief Product Officer
Comp: $228k
Dr. Brian Ember (Age 48)
Chief Executive Officer of AgPlenus Ltd
Comp: $287k
Dr. Elran Hillel Haber M.B.A. (Age 44)
Ph.D., Chief Executive Officer of Biomica Ltd
Comp: $302k
Mr. Amit Noam Capt. res. (Age 42)
Chief Executive Officer of Lavie Bio Ltd.
Comp: $136k
Mr. Yaron Eldad (Age 59)
Chief Financial Officer
Mr. Mark Kapel (Age 47)
Chief Technology Officer
Comp: $276k
Rachel Pomerantz Gerber
Head of Investor Relations
Mr. Sassi Masliah (Age 45)
Vice President of Corporate Development
Comp: $245k
Ms. Liat Foigel Wejgman
Vice President of Human Resources

Key Competitors

View All Competitors

Institutional Ownership

Simplex Trading LLC
Bought 5,000 shares on 2/2/2024
Ownership: 0.000%

View All Institutional Transactions

EVGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Evogene stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings or view top-rated stocks.
What is Evogene's stock price target for 2024?: 3 equities research analysts have issued 1 year price objectives for Evogene's shares. Their EVGN share price targets range from $1.85 to $6.00. On average, they anticipate the company's stock price to reach $3.62 in the next twelve months. This suggests a possible upside of 491.0% from the stock's current price.
View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts.
How have EVGN shares performed in 2024?: Evogene's stock was trading at $0.84 on January 1st, 2024. Since then, EVGN shares have decreased by 27.1% and is now trading at $0.6120.
View the best growth stocks for 2024 here.
Are investors shorting Evogene?: Evogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 86,500 shares, an increase of 20.8% from the March 15th total of 71,600 shares. Based on an average trading volume of 173,900 shares, the days-to-cover ratio is currently 0.5 days.
View Evogene's Short Interest.

When is Evogene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our EVGN earnings forecast.
How were Evogene's earnings last quarter?: Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $0.58 million for the quarter, compared to analysts' expectations of $1.73 million. Evogene had a negative net margin of 423.39% and a negative trailing twelve-month return on equity of 76.93%. During the same quarter last year, the firm posted ($0.07) earnings per share.
What other stocks do shareholders of Evogene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Abbott Laboratories (ABT), Acasti Pharma (ACST) and Akari Therapeutics (AKTX).
How do I buy shares of Evogene?: Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Evogene (EVGN) Stock Price, News & Analysis

Evogene MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Evogene Stock (NASDAQ:EVGN)

EVGN Stock Price History

EVGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

EVGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™